Two humanized antibodies targeting the ECL2 of CLDN4 (KM3934 and xi-5D12, Table 1), demonstrated ADCC when co-cultured with human Peripheral Blood Mononuclear Cells (PBMCs) and ovarian cancer cells (KM3934) or human and mouse CLDN4 expressing cells (xi-5D12), respectively (46, 47). The gene discussed is CLDN4; the disease is ovarian carcinoma.